{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:23:47Z","timestamp":1791260627386,"version":"4.1.0"},"reference-count":109,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2013,7,23]],"date-time":"2013-07-23T00:00:00Z","timestamp":1374537600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2013,8]]},"abstract":"<jats:p>Despite considerable effort, application of monoclonal antibody technology has had only modest success in improving treatment outcomes in patients with solid tumours. Enhancing the cancer cell\u2010killing activity of antibodies through conjugation to highly potent cytotoxic \u2018payloads\u2019 to create antibody\u2013drug conjuates (<jats:styled-content style=\"fixed-case\">ADCs<\/jats:styled-content>) offers a strategy for developing anti\u2010cancer drugs of great promise. Early <jats:styled-content style=\"fixed-case\">ADCs<\/jats:styled-content> exhibited side\u2010effect profiles similar to those of \u2018classical\u2019 chemotherapeutic agents and their performance in clinical trials in cancer patients was generally poor. However, the recent clinical development of <jats:styled-content style=\"fixed-case\">ADCs<\/jats:styled-content> that have highly potent tubulin\u2010acting agents as their payloads have profoundly changed the outlook for <jats:styled-content style=\"fixed-case\">ADC<\/jats:styled-content> technology. Twenty\u2010five such <jats:styled-content style=\"fixed-case\">ADCs<\/jats:styled-content> are in clinical development and one, brentuximab vedotin, was approved by the <jats:styled-content style=\"fixed-case\">FDA<\/jats:styled-content> in <jats:styled-content style=\"fixed-case\">A<\/jats:styled-content>ugust, 2011, for the treatment of patients with Hodgkin's lymphoma and patients with anaplastic large cell lymphoma, based on a high rate of durable responses in single arm phase <jats:styled-content style=\"fixed-case\">II<\/jats:styled-content> clinical trials. More recently, a second <jats:styled-content style=\"fixed-case\">ADC<\/jats:styled-content>, trastuzumab emtansine, has shown excellent anti\u2010tumour activity with the presentation of results of a 991\u2010patient randomized phase <jats:styled-content style=\"fixed-case\">III<\/jats:styled-content> trial in patients with <jats:styled-content style=\"fixed-case\">HER2<\/jats:styled-content>\u2010positive metastatic breast cancer. Treatment with this <jats:styled-content style=\"fixed-case\">ADC<\/jats:styled-content> (single agent) resulted in a significantly improved progression\u2010free survival of 9.6 months compared with 6.4 months for lapatinib plus capecitabine in the comparator arm and significantly prolonged overall survival. Besides demonstrating excellent efficacy, these <jats:styled-content style=\"fixed-case\">ADCs<\/jats:styled-content> were remarkably well tolerated. Thus these, and other <jats:styled-content style=\"fixed-case\">ADCs<\/jats:styled-content> in development, promise to achieve the long sought goal of <jats:styled-content style=\"fixed-case\">ADC<\/jats:styled-content> technology, that is, of having compounds with high anti\u2010tumour activity at doses where adverse effects are generally mild.<\/jats:p>","DOI":"10.1111\/bcp.12044","type":"journal-article","created":{"date-parts":[[2012,11,23]],"date-time":"2012-11-23T08:28:21Z","timestamp":1353659301000},"page":"248-262","source":"Crossref","is-referenced-by-count":135,"title":["Drug\u2010conjugated antibodies for the treatment of cancer"],"prefix":"10.1111","volume":"76","author":[{"given":"John M.","family":"Lambert","sequence":"first","affiliation":[{"name":"ImmunoGen, Inc  830 Winter Street Waltham MA 02451 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,7,23]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/256495a0"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1309\/5CWPU41AFR1VYM3F"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2825"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2007.125"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-59745-554-1_1"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60251-8"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6446(03)02714-4"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-409X(97)00095-1"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2005.04.017"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1021\/bk-2001-0796.ch019"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1358\/dof.2010.035.06.1497487"},{"key":"e_1_2_5_13_1","first-page":"331","volume-title":"Macromolecular Anticancer Therapeutics, Cancer Drug Discovery and Development 2010, Part 4","author":"Vater CA","year":"2010"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0b013e318172d704"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm9600398"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0486"},{"key":"e_1_2_5_17_1","first-page":"1490","article-title":"Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia","volume":"7","author":"Bross PF","year":"2001","journal-title":"Clin Cancer Res"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.13.3244"},{"key":"e_1_2_5_19_1","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1182\/blood.V114.22.790.790","article-title":"Preliminary results of Southwest Oncology Group Study SO106: an international intergroup phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomized to post\u2010consolidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia","volume":"114","author":"Petersdorf S","year":"2009","journal-title":"Blood"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.2693"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.4310"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60485-1"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.1900"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20010715)92:2<406::AID-CNCR1336>3.0.CO;2-U"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-01-0255"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70386-2"},{"key":"e_1_2_5_27_1","article-title":"Single, low dose treatment of lymphoma and renal cancer xenografts with human anti\u2010CD70 antibody\u2010toxin conjugates, results in long term cures","volume":"48","author":"Terrett JA","year":"2007","journal-title":"Proc Am Assoc Cancer Res"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-0204"},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3253"},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-416039-2.00006-9"},{"key":"e_1_2_5_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2289"},{"key":"e_1_2_5_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-396492-2.00023-0"},{"key":"e_1_2_5_33_1","doi-asserted-by":"publisher","DOI":"10.1110\/ps.051478705"},{"key":"e_1_2_5_34_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-012-9386-x"},{"key":"e_1_2_5_35_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-11-0727"},{"key":"e_1_2_5_36_1","first-page":"84","article-title":"Disulfide\u2010linked antibody\u2010maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage","volume":"21","author":"Kellogg BA","year":"2011","journal-title":"Bioconjug Chem"},{"key":"e_1_2_5_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-01-0039"},{"key":"e_1_2_5_38_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0410"},{"key":"e_1_2_5_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0402"},{"key":"e_1_2_5_40_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002965"},{"key":"e_1_2_5_41_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-1425"},{"key":"e_1_2_5_42_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.8070","article-title":"Brentuximan vedotin for relapsed or refractory non\u2010Hodgkin lymphoma: preliminary results from a phase 2 study","volume":"30","author":"Advani R","year":"2012","journal-title":"J Clin Oncol"},{"key":"e_1_2_5_43_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-1776"},{"key":"e_1_2_5_44_1","doi-asserted-by":"publisher","DOI":"10.1021\/bc900315y"},{"key":"e_1_2_5_45_1","doi-asserted-by":"publisher","DOI":"10.2174\/138920012802138598"},{"key":"e_1_2_5_46_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.2071"},{"key":"e_1_2_5_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27622"},{"key":"e_1_2_5_48_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.5865"},{"issue":"8","key":"e_1_2_5_49_1","first-page":"viii97","article-title":"A phase 2 study of the HER2 antibody\u2010drug conjugate trastuzumab\u2010DM1 (T\u2010DM1) in patients (pts) with HER2\u2010positive metastatic breast cancer (MBC) previously treated with trastuzumab, lapatinib, and chemotherapy","volume":"21","author":"Krop I","year":"2010","journal-title":"Ann Oncol"},{"key":"e_1_2_5_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-011-1817-3"},{"key":"e_1_2_5_51_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2010.12"},{"key":"e_1_2_5_52_1","doi-asserted-by":"publisher","DOI":"10.1039\/c1cc14164c"},{"key":"e_1_2_5_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(11)71443-5"},{"key":"e_1_2_5_54_1","article-title":"Cardiac safety in a phase II study of trasuzumab emtansine (T\u2010DM1) following anthracycline\u2010based chemotherapy as adjuvant or neoadjuvant therapy for early\u2010stage HER2\u2010positive breast cancer","volume":"30","author":"Dang CT","year":"2012","journal-title":"J Clin Oncol"},{"key":"e_1_2_5_55_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209124"},{"key":"e_1_2_5_56_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.e13502","article-title":"Potentiation of trastuzumab emtansine (T\u2010DM1)\u2010driven antitumor activity by pertuzumab in a HER2\u2010positive gastric cancer model","volume":"30","author":"Yamashita\u2010Kashima Y","year":"2012","journal-title":"J Clin Oncol"},{"key":"e_1_2_5_57_1","doi-asserted-by":"publisher","DOI":"10.1177\/1758834012451205"},{"key":"e_1_2_5_58_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-2018"},{"key":"e_1_2_5_59_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1611"},{"key":"e_1_2_5_60_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2010.28.15_suppl.8525","article-title":"Frequent dosing and GPNMB expression with CDX\u2010011 (CR011\u2010vcMMAE), an antibody\u2010drug conjugate (ADC), in patients with advanced melanoma","volume":"28","author":"Hamid O","year":"2010","journal-title":"J Clin Oncol"},{"key":"e_1_2_5_61_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2010.28.15_suppl.1095","article-title":"Correlation of GPNMB expression with outcome in breast cancer (BC) patients treated with the antibody\u2010drug conjugate (ADC), CDX\u2010011 (CR011\u2010vcMMAE)","volume":"28","author":"Saleh M","year":"2010","journal-title":"J Clin Oncol"},{"key":"e_1_2_5_62_1","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.4049\/jimmunol.130.6.2947","article-title":"Characterization of an antigen expressed by human natural killer cells","volume":"130","author":"Griffin JD","year":"1983","journal-title":"J Immunol"},{"key":"e_1_2_5_63_1","doi-asserted-by":"publisher","DOI":"10.1093\/protein\/9.10.895"},{"key":"e_1_2_5_64_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.146.12.4421"},{"key":"e_1_2_5_65_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-0142"},{"key":"e_1_2_5_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2007.09.004"},{"key":"e_1_2_5_67_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/88.16.1136"},{"key":"e_1_2_5_68_1","article-title":"Preclinical evaluation of IMGN901 (huN901\u2010DM1) as a potential therapeutic for ovarian cancer","volume":"49","author":"Whiteman KR","year":"2008","journal-title":"Proc Am Assoc Cancer Res"},{"key":"e_1_2_5_69_1","unstructured":"ChariRVJ XieH SteevesRM LambertJM.Additive and synergistic effects of combination treatment with huN901\u2010DM1 (BB\u201010901) and chemotherapeutic agents in small cell lung cancer xenograft tumor models. Proceedings of AACR\u2010NCI\u2010EORTC International Conference: Molecular Targets and Cancer Therapeutics.2005;70 abstr A58."},{"key":"e_1_2_5_70_1","article-title":"Phase I study of IMGN901 (BB\u201010901) in patients with CD56\u2010positive solid tumors","volume":"6","author":"Woll P","year":"2008","journal-title":"Eur J Cancer"},{"issue":"8","key":"e_1_2_5_71_1","article-title":"Phase I study of lorvotuzumab mertansine (IMGN901) in patients with CD56\u2010positive solid tumors","volume":"21","author":"Woll PJ","year":"2010","journal-title":"Ann Oncol"},{"key":"e_1_2_5_72_1","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1182\/blood.V116.21.1962.1962","article-title":"Efficacy analysis from a phase I study of lorvotuzumab mertansine (IMGN901) used as monotherapy in patients with heavily pre\u2010treated CD56\u2010positive multiple myeloma","volume":"116","author":"Chanan\u2010Khan A","year":"2010","journal-title":"Blood"},{"key":"e_1_2_5_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(02)81163-7"},{"issue":"18","key":"e_1_2_5_74_1","article-title":"Phase II trial of huN901\u2010DM1 in patients with relapsed small cell lung cancer (SCLC) and CD56\u2010positive small cell carcinoma","volume":"25","author":"McCann J","year":"2007","journal-title":"J Clin Oncol"},{"key":"e_1_2_5_75_1","unstructured":"FossellaF WollPJ LoriganP TolcherA O'BrienM O'KeeffeJ ZildjianS QinA O'LearyJ Villalona\u2010CaleroM.Clinical experience of IMGN901 (BB\u201010901) in patients with small cell lung carcinoma. J Thorac Oncol [13th World Conference on Lung Cancer 2009]2009; 4(Suppl. 9) Abstr 6327. (PD4.3.5)."},{"key":"e_1_2_5_76_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.8013","article-title":"Phase I study of lorvotuzumab mertansine (LM, IMGN901) in combination with lenalidomide (Len) and dexamethasone (Dex) in patients with CD56\u2010positive relapsed or relapsed\/refractory multiple myeloma (MM)","volume":"29","author":"Berdeja JG","year":"2011","journal-title":"J Clin Oncol"},{"key":"e_1_2_5_77_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.329"},{"key":"e_1_2_5_78_1","article-title":"The antigen target of lorvotuzumab mertansine (IMGN901), CD56, is expressed at significant levels in Merkel cell carcinoma (MCC)","volume":"51","author":"Carrigan CN","year":"2010","journal-title":"Proc Am Assoc Cancer Res"},{"key":"e_1_2_5_79_1","article-title":"Efficacy of IMGN901 (huN901\u2010DM1) in combination with bortezomib and lenalidomide against multiple myeloma cells in preclinical studies","volume":"49","author":"Whiteman KR","year":"2008","journal-title":"Proc Am Assoc Cancer Res"},{"key":"e_1_2_5_80_1","article-title":"Lorvotuzumab mertansine (IMGN901) in combination with standard\u2010of\u2010care paclitaxel\/carboplatin therapy is highly active in a preclinical xenograft model of ovarian cancer","volume":"52","author":"Whiteman KR","year":"2011","journal-title":"Proc Am Assoc Cancer Res"},{"key":"e_1_2_5_81_1","article-title":"Combination therapy with IMGN901 and lenalidomide plus low\u2010dose dexamethasone is highly effective in multiple myeloma xenograft models","volume":"50","author":"Whiteman KR","year":"2009","journal-title":"Proc Am Assoc Cancer Res"},{"key":"e_1_2_5_82_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.1934.1934","article-title":"Phase I study of lorvotuzumab mertansine (IMGN901) in combination with lenalidomide and dexamethasone in patients with CD56\u2010positive relapsed or relapsed\/refractory multiple myeloma \u2013 a preliminary safety and efficacy analysis of the combination","volume":"116","author":"Berdeja JG","year":"2010","journal-title":"Blood"},{"issue":"9","key":"e_1_2_5_83_1","article-title":"Phase I\/II study to assess the safety, pharmacokinetics (PK) and efficacy of lorvotuzumab mertansine (LM, IMGN901) in combination with carboplatin\/etoposide in patients with solid tumors including small\u2010cell lung cancer (SCLC). 37th ESMO Congress, Vienna","volume":"23","author":"Spigel DR","year":"2012","journal-title":"Ann Oncol"},{"key":"e_1_2_5_84_1","doi-asserted-by":"crossref","first-page":"244","DOI":"10.4049\/jimmunol.131.1.244","article-title":"B4, a human B lymphocyte\u2010associated antigen expressed on normal, mitogen activated, and malignant B lymphocytes","volume":"131","author":"Nadler LM","year":"1983","journal-title":"J Immunol"},{"key":"e_1_2_5_85_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.3.969"},{"key":"e_1_2_5_86_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0485"},{"key":"e_1_2_5_87_1","article-title":"Preclinical evaluation of SAR3419 (huB4\u2010DM4), an anti\u2010CD19\u2010maytansinoid immunoconjugate, for the treatment of B\u2010cell lymphoma","volume":"47","author":"Lutz RJ","year":"2006","journal-title":"Proc Am Assoc Cancer Res"},{"key":"e_1_2_5_88_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-2808"},{"key":"e_1_2_5_89_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.585.585","article-title":"Phase I multi\u2010dose escalation study of the anti\u2010CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous (IV) infusion every 3 weeks to patients with relapsed\/refractory B\u2010cell non\u2010Hodgkin's lymphoma (NHL)","volume":"114","author":"Younes A","year":"2009","journal-title":"Blood"},{"key":"e_1_2_5_90_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.4403"},{"key":"e_1_2_5_91_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.8017","article-title":"Phase I\/II study of the anti\u2010CD19 maytansinoid immunoconjugate SAR3419 administered weekly to patients (pts) with relapsed\/refractory B\u2010cell non\u2010Hodgkin lymphoma (NHL)","volume":"29","author":"Coiffier B","year":"2011","journal-title":"J Clin Oncol"},{"key":"e_1_2_5_92_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.8057","article-title":"Phase I study cohort evaluating an optimized administration schedule of SAR3419, an anti\u2010CD19 DM4\u2010loaded antibody\u2010drug conjugate (ADC), in patients (pts) with CD19 positive relapsed\/refractory B\u2010cell non\u2010Hodgkin's lymphoma (NCT00796731)","volume":"30","author":"Coiffier B","year":"2012","journal-title":"J Clin Oncol"},{"key":"e_1_2_5_93_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0916"},{"key":"e_1_2_5_94_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.3071","article-title":"SGN75: the effect of SGN\u201075, a novel antibody\u2013drug conjugate (ADC), in treatment of patients with renal cell carcinoma (RCC) or non\u2010Hodgkin lymphoma (NHL): a phase I study","volume":"29","author":"Thompson JA","year":"2011","journal-title":"J Clin Oncol"},{"key":"e_1_2_5_95_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-11-0191"},{"key":"e_1_2_5_96_1","article-title":"Prostate\u2010specific membrane antigen antibody drug conjugate (PSMA ADC): a phase I trial in metastatic castration\u2010resistant prostate cancer (mCPRC) previously treated with a taxane","volume":"30","author":"Mega AE","year":"2012","journal-title":"J Clin Oncol"},{"key":"e_1_2_5_97_1","doi-asserted-by":"crossref","unstructured":"GudasJM TorgoM AnZ JiaXC MorrisonKJ MorrisonRK KannerSB RaitanoAB JakobovitsA.AGS\u201016M8F: a novel antibody\u2010drug conjugate (ADC) for treating renal and lier cancers.ASCO Genitourinary Cancers Symposium2010. abstr 328.","DOI":"10.1158\/1538-7445.AM10-2436"},{"key":"e_1_2_5_98_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.4568","article-title":"Phase I trial of ASG\u20105ME in metastatic castration\u2010resistant prostate cancer (CRPC)","volume":"30","author":"Morris MJ","year":"2012","journal-title":"J Clin Oncol"},{"key":"e_1_2_5_99_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-0963"},{"key":"e_1_2_5_100_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-2867"},{"key":"e_1_2_5_101_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.305.305","article-title":"BT062, an antibody\u2010drug conjugate directed against CD138, shows clinical activity in patients with relapsed or relapsed\/refractory multiple myeloma","volume":"118","author":"Jagannath S","year":"2011","journal-title":"Blood"},{"key":"e_1_2_5_102_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.21697"},{"key":"e_1_2_5_103_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6349(08)72459-5"},{"issue":"8","key":"e_1_2_5_104_1","article-title":"Efficacy and candidate biomarker evaluation for the anti\u2010mesothelin antibody drug conjugate (ADC) BAY 94\u20109343, mesothelin\u2010ADC in mesothelin\u2010positive preclinical xenograft models","volume":"72","author":"Schatz CA","year":"2012","journal-title":"Proc Am Assoc Cancer Res"},{"key":"e_1_2_5_105_1","article-title":"Antibody and linker selection for the anti\u2010CD37 antibody\u2010maytansinoid conjugate IMGN529 for the treatment of B\u2010cell malignancies","volume":"71","author":"Park PU","year":"2011","journal-title":"Proc Am Assoc Cancer Res"},{"key":"e_1_2_5_106_1","article-title":"IMGN529: a therapeutic maytansinoid conjugate of an anti\u2010CD37 antibody with multiple mechanisms of action for B\u2010cell lymphoma and leukemia","volume":"71","author":"Deckert J","year":"2011","journal-title":"Proc Am Assoc Cancer Res"},{"key":"e_1_2_5_107_1","article-title":"IMGN853, an anti\u2010folate receptor I antibody\u2010maytansinoid conjugate for targeted cancer therapy","volume":"71","author":"Ab O","year":"2011","journal-title":"Proc Am Assoc Cancer Res"},{"key":"e_1_2_5_108_1","article-title":"Preclinical evaluation of IMGN853, an anti\u2010FOLR1 antibody\u2010maytansinoid conjugate, as a potential therapeutic for ovarian cancer","volume":"71","author":"Whiteman KR","year":"2011","journal-title":"Proc Am Assoc Cancer Res"},{"key":"e_1_2_5_109_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-04-420968"},{"key":"e_1_2_5_110_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-012-1934-7"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.12044","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.12044","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T02:25:13Z","timestamp":1694571913000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.12044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,23]]},"references-count":109,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["10.1111\/bcp.12044"],"URL":"https:\/\/doi.org\/10.1111\/bcp.12044","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,23]]}}}